Risk factors in venous thromboembolism

Thrombosis and Haemostasis

Volumn 86, Issue 1, 2001, Pages 395-403

  Martinelli, I ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Coagulation; Gene environment interaction; Thrombophilia; Thrombosis

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT PROTEIN; ANTITHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; DESOGESTREL; ESTROGEN; FIBRINOGEN; GESTAGEN; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ACTIVATED PROTEIN C RESISTANCE; AGE; ANAMNESIS; BLOOD CLOTTING; CANCER; CAUCASIAN; CONFERENCE PAPER; DYSFIBRINOGENEMIA; ENVIRONMENTAL FACTOR; GENE MUTATION; GENERAL SURGERY; GENETIC DISORDER; HEREDITY; HORMONE SUBSTITUTION; HUMAN; HYPERHOMOCYSTEINEMIA; IMMOBILIZATION; INJURY; LUNG EMBOLISM; MOLECULAR BIOLOGY; NUCLEIC ACID BASE SUBSTITUTION; POPULATION RESEARCH; POSTTHROMBOSIS SYNDROME; PREGNANCY; PRIORITY JOURNAL; PUERPERIUM; RECURRENT DISEASE; RISK FACTOR; THROMBOEMBOLISM; THROMBOPHILIA; VEIN THROMBOSIS;

EID: 0034912185     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616237     Document Type: Conference Paper

References (144)

1. Inherited thrombophilia: Part 1
2. Inherited thrombophilia: Part 2
3. Inherited antithrombin deficiency causing thrombophilia
4. Antithrombin III deficiency and thromboembolism
5. Thrombosis in antithrombin III-deficient persons: Report of a large kindred and literature review
6. Deficiency of protein C in congenital thrombotic disease
7. Congenital protein C deficiency and venous thromboembolism: A study of three Dutch families
8. Plasma protein S defeciency in familial thrombotic disease
9. Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn
10. Coumarin necrosis associated with hereditary protein C deficiency
11. Inherited thrombophilia: Pathogenesis, clinical syndromes, and management
12. Prevalence of antithrombin III deficiency subtypes in 4000 healthy blood donors
13. Prevalence of antithrombin deficiency in the healthy population
14. Absence of thrombosis in subjects with heterozygous protein C deficiency
15. Prevalence of protein C deficiency in the healthy population
16. Deep-vein thrombosis
17. Approach to the thrombophilic patients
18. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: A study of 150 families
19. Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency or activated protein C resistance
20. The incidence of venous thromboembolism in asymptomatic carriers of deficiency of antithrombin, protein C, or protein S: A prospective cohort study
21. Gene-gene and gene-environment interactions determine risk of thrombosis in families with inherited antithrombin deficiency
22. Protein C deficiency in a controlled series of unselected outpatients: An infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study)
23. Familial thrombophilia due to a previously unrecognized mechanim characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C
24. Mutation in blood coagulation factor V associated with resistance to activated protein C
25. World distribution of factor V Leiden
26. Resistance to activated protein C as a basis for venous thrombosis
27. Venous thrombosis due to a poor anticoagulant response to activated protein C: Leiden Thrombophilia Study
28. Anticoagulant protein C pathway defective in a majority of thrombophilic patients
29. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis
30. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men
31. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance)
32. Genetic risk factors for superficial vein thrombosis
33. Low prevalence of factor V:Q506 in 41 patients with isolated pulmonary embolism
34. Is the prevalence of the factor V Leiden mutation in patients with pulmonary embolism and deep vein thrombosis really different?
35. Factor V Leiden and fatal pulmonary embolism
36. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
37. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene
38. Geographic distribution of the 20210G to A prothrombin variant
39. The prothrombin gene G20210A variant: Prevalence in a U.K. anticoagulant clinic population
40. The 20210A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis
41. Risk of venous thromboembolism associated with a G to A transition at position 20210 in 3′untranslated region of the prothrombin gene
42. The prothrombin 20210A allele is the most present genetic risk factor for venous thromboembolism in the Spanish population
43. Prevalence of the 20210A allele of the prothrombin gene in venous thromboembolism patients
44. Increased risk for venous thrombosis in carriers of the prothrombin G20210A gene variant
45. The risk of venous thromboembolism in family members with mutations in the genes of factor V, prothrombin or both
46. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation
47. The epidemiology, pathogenesis and natural history of venous thrombosis
48. A prospective study of the incidence of deep-vein thrombosis within a defined urban population
49. A population based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study
50. Age-specific incidence rates of venous thromboembolism among heterogzygous carriers of factor V Leiden mutation
51. Factor V Leiden and venous thrombosis in Danish centenarians
52. The risk of mortality and the factor V Leiden mutation in a population-based cohort
53. Mutant factor V (Arg506Gln) in healthy centenarians
54. Correlates of antithrombin, protein C, protein S and TFPI in a healthy elderly cohort
55. Leukocytes and tumor cells in thrombosis
56. Pharmacology of heparin and oral anticoagulants
57. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer
58. Occult cancer in patients with deep venous thrombosis
59. Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep venous thrombosis
60. Cancer and venous thromboembolism
61. Occult malignant neoplasm in patients with deep venous thrombosis
62. Undiagnosed malignancy in patients with deep vein thrombosis: Incidence, risk indicators, and diagnosis
63. The risk of diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism
64. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism
65. Antiphospholipid antibodies and venous thromboembolism
66. Deep venous thrombosis and lupus anticoagulant
67. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism-results of the Spanish multicentric study on thrombophilia (EMET-study)
68. The management of thrombosis in the antiphospholipid-antibody syndrome
69. Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip replacement
70. Clinical factors and the risk of deep venous thrombosis
71. The epidemiology of lower extremity deep venous thrombosis in surgical patients
72. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis
73. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis
74. Hyperhomocysteinemia, atherosclerosis and thrombosis
75. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis
76. Methylenetetrahydrofolate reductase polymorphism, plasma folate homocysteine, and risk of myocardial infarction in US physicians
77. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and the risk of future venous thromboembolism
78. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism
79. Thermolabile methylenetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis
80. Vitamins as homocysteine-lowering agents
81. Role of clotting factor VIII in effect of von Willebrand factor an occurrence of deep-vein thrombosis
82. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: Role of increased synthesis and relationship to acute phase reaction
83. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism
84. Elevation of FVIII:C in venous thromboembolism is persistent and independent of the acute phase response
85. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism
86. High levels of factor IX increase the risk of venous thrombosis
87. High levels of coagulation factor XI as a risk factor for venous thrombosis
88. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis
89. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C
90. A factor V genetic component differing from factor V R506Q contributed to the activated protein C resistance phenotype
91. Factor V Cambridge: A new mutation (Arg30®Thr) associated with resistance to activated protein C
92. Development of resistance to activated protein C during pregnancy
93. Low-dose oral contraceptives and acquired resistance to activated protein C: A randomised cross-over study
94. Activated protein resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism
95. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis
96. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC subcommittee on fibrinogen
97. Congenital abnormalities of fibrinogen
98. Factor VII and fibrinogen levels as risk factors for venous thrombosis
99. Role of genetic variation in the fibrinogen locus in determination of plasma fibrinogen concentrations
100. Variation in the promotor region of the b fibrinogen gene is associated with plasma fibrinogen levels in smokers and non-smokers
101. Prevention of postoperative venous thromboembolism: An update
102. Prophylaxis of venous thromboembolic disease following hip and knee surgery
103. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery
104. Venous thrombosis after elective hip replacement: The influence of preventive intermittent calf compression and of surgical technique
105. Low-molecular weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement
106. A prospective study of venous thromboembolism after major trauma
107. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma
108. The cumulative incidence of venous thromboembolism during pregnancy and puerperium
109. Thrombotic risk during pregnancy: A population study
110. Epidemiological observations of thrombo-embolic disease during pregnancy and in the puerperium, in 56,022 women
111. Deep vein thrombosis during pregnancy and the puerperium: A meta-analysis of the period of risk and the leg of presentation
112. The incidence of the factor V Leiden mutation in an obstetric population and its relationship to deep vein thrombosis
113. Role of thrombophilia in venous thromboembolism during pregnancy and puerperium
114. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia
115. Oral contraceptive estrogen dose and the risk for deep venous thromboembolic disease
116. Oral contraceptive and thrombotic disease: Risk of venous thromboembolism
117. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception
118. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components
119. Third generation oral contraceptives and risk of venous thromboembolic disorders: An international case-control study. Transitional Research Group on Oral Contraceptives and the Health of Young Women
120. The increased risk of venous thromboembolism and the use of third generation progestagens: Role of bias in observational research. The Trasnational Research Group in Oral Contraceptives and the Health of Young Women
121. Population-based study of risk of venous thromboembolism associated with various oral contraceptives
122. Bias in analytic research
123. The 1995 pill scare revisited: Anatomy of a non-epidemic
124. Newer oral contraceptives and the risk of venous thromboembolism
125. The association between oral contraceptives and venous thrombosis: The myth of the diagnostic suspicion- and referral bias
126. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis
127. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives
128. Risk of venous thromboembolism in users of hormone replacement therapy
129. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
130. Prospective study of exogenous hormones and risk of pulmonary embolism in women
131. Venous thromboembolic events associated with hormone replacement therapy
132. Venous thrombosis of the lower limbs with particular reference to bed rest
133. Thrombosis and embolism after injury
134. Probability of recurrence of thrombosis in patients with and without factor V Leiden
135. Coexistence of factor V Leiden and factor II A20210 mutations and recurrent venous thromboembolism
136. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden
137. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombine gene
138. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism
139. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with G20210A transition in the prothrombin gene
140. Factor V Leiden and the risks of recurrent idiopathic venous thromboembolism
141. The risk of recurrent venous thromboembolism in patients with an Arg506→Gln mutation in the gene for factor V (factor V Leiden)
142. Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis
143. Recurrent deep vein thrombosis and two coagulation factor gene mutations: Quo vadis?